Treatment
Ipilimumab clinical trials
We’re tracking 118 recruiting studies that include Ipilimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06031233RecruitingPhase 4
Shorter infusion times for cancer immunotherapy drugs
This trial tests if giving common immunotherapy drugs over a shorter time is safe. It may mean less time in the clinic for you.
ZwolleAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT05647265RecruitingPhase 2
Immunotherapy before surgery for sarcomatoid pleural mesothelioma
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Anchorage, AlaskaAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT05536141RecruitingPhase 1
Study of AB521 for kidney cancer and other solid tumors
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Birmingham, AlabamaAges 18 years+ - NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Birmingham, AlabamaAges 18 years+ - NCT05254184RecruitingPhase 1
Vaccine and immunotherapy for KRAS-mutated lung cancer
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Baltimore, MarylandAges 18–100 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT04697576RecruitingPhase 1
Flu vaccine injected into melanoma tumors for stage I-IV
This trial tests whether injecting a flu vaccine directly into melanoma tumors helps shrink them. It is for people with stage I to IV melanoma who have at least one tumor that can be injected.
Columbus, OhioAges 18–99 - NCT04665206RecruitingPhase 1/Phase 2
Testing VT3989 for certain advanced cancers
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
San Francisco, CaliforniaAges 18 years+ - NCT04566380RecruitingPhase 2
Study for people already taking ONO-4538
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Chiba, ChibaAges 16 years+ - NCT04472767RecruitingPhase 2
Cabozantinib with immunotherapy plus TACE for liver cancer
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
Orange, CaliforniaAges 18 years+ - NCT03899155RecruitingPhase 2
Study for continuing or restarting cancer treatment that worked before
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Huntsville, AlabamaAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03340129RecruitingPhase 2
Nivolumab plus focused brain radiation for melanoma spread
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Sydney, New South WalesAges 18–120 - NCT03026140RecruitingPhase 2
Tested immune therapy before surgery for early colon cancer
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
AmsterdamAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Birmingham, AlabamaAges 12 years+
Common questions
- Are there clinical trials studying Ipilimumab?
- Yes. Clin2 currently lists 118 recruiting studies that include Ipilimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ipilimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ipilimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ipilimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.